Autonomix presents early preclinical research on renal denervation sensing technology
AMIX•Autonomix Medical presented preliminary healthy-swine research on its investigational sensing catheter at TCT 2026. The company is targeting a commercial offering by the end of 2028, subject to development, validation, financing and regulatory authorization.
1. Preliminary swine findings
Autonomix Medical said healthy swine studies captured electrical activity before and after ablation. The findings are preliminary and require further validation; reduced recorded activity alone does not establish complete or durable denervation.
2. Commercialization plans
The standalone sensing system is Autonomix’s initial U.S. commercialization priority. The company said proposed initial clearance would exclude renal denervation guidance or treatment-verification claims, and it is targeting a commercial offering by the end of 2028, subject to successful development, validation, financing and regulatory authorization.
